When I think of an overdose, I think of someone dying or at least coming close to it; the truth is, consuming more of a substance than we can handle is scary, even when not fatal. Thankfully, overdosing on cannabis is not really physiologically possible, and there is a lot one can do to mitigate the […]
How many of us look forward to a drink at the end of a hard work week? Some even look forward to it after a particularly hard day. From going out for drinks with friends or healing a broken heart, we all have our reasons to partake. Sprinkle a little bit of Covid into the […]
Opioids and cannabis are primarily used as analgesics. Both function remarkably well for relieving chronic pain. Since the start of medical cannabis programs in states across the U.S. and Canada, statistics show that patients prefer the use of cannabis to opioids. This caused a 40% reduction in the use of opioids
Due to this shift in paradigm, the DEA was forced to shift their stance on certain drugs. First with cannabis and now with psychedelics. The public had to twist the arm of the government in order to have them say, “Sure we’re thinking about making it easier to research…just give us time!”
Since 1971, a single facility at the University of Mississippi has been in charge of producing cannabis plants for research purposes at the federal level. This monopoly prevented other facilities (public and private-owned) from growing marijuana for experimental reasons. In 2016, the DEA began to remove the monopoly on marijuana for medical research. Finally, they achieved what they set out to do in May 2021. The applications of several cannabis companies were approved by mid-2021. Groff Hemplex and the Biopharmaceutical Research Company revealed that they have been fully registered in the DEA database and have started cultivating cannabis plants. The first phase of harvest, which started about a month ago, will be forwarded to research facilities. Marijuana researchers across the country have commended this development.
Marijuana Moment write A top federal drug official says the “train has left the station” on psychedelics. National Institute on Drug Abuse (NIDA) Director Nora Volkow said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers […]
GOP members in Congress proposed a new bill called Halt All Lethal Trafficking (HALT) Fentanyl. This bill would kickstart a deeper study of Schedule 1 substances. The Republicans who filed these companion bills are Senator Bill Cassidy, Bob Latta, and Representative Morgan Griffith. Both of them drafted the bills asked on a plan which was announced by the White House's Office of National Drug Control Policy (ONDCP).